Vicebio aims to deliver vaccines that are highly effective, easy to manufacture, and ready-to-use in prefilled syringes.
The key to achieving this result lies in using a novel approach called molecular clamp technology.
It is licensed exclusively to Vicebio through Uniquest, the universitys commercialisation arm.
This effect can stimulate a stronger immune response.
It could also initiate the startup to simplify the manufacturing process, potentially making its vaccines more cost-effective.
It’s free, every week, in your inbox.
The company will also use the funding to expand its vaccine portfolio.
However, it will have to compete with AstraZenecas recently acquired Icosavax.
Icosavax has progressed to Phase 2 with its own RSV/hMPV vaccine.
Vicebio expects the results of VXB-241s Phase 1 in mid-2025.
Story byIoanna Lykiardopoulou
Ioanna is a writer at TNW.
With a background in the humanities, she has a soft spot for social impact-enabling technologies.
